Specialty generic pharmaceutical company Sun Pharmaceutical Industries has formally entered the Philippine primary care segment with the launch of CaRMeLin Portfolio, a new therapeutic portfolio covering cardiometabolic, renal, liver and alimentary conditions.
The launch event in Manila gathered key opinion leaders from internal medicine, cardiology, endocrinology, nephrology and primary care. It signaled the company’s move to strengthen its presence in the local market through a broader range of treatment options.
A keynote lecture by Dr. Raymond Townsend, professor of medicine at the University of Pennsylvania and a specialist in hypertension and chronic kidney disease, anchored the scientific program. Serving as scientific chair, Dr. Gerry Tan, an endocrinologist trained at the Mayo Clinic, highlighted the implications of the expansion for local healthcare.
“As the world’s fourth-largest specialty generic company, Sun Pharma’s launch in the Philippines sets a new benchmark in manufacturing excellence and strengthens the country’s supply security for affordable specialty generics,” Tan said. “In critical fields like mine — diabetes and endocrinology — where precision and bioequivalence are non-negotiable, this is a true game-changer for Filipino patients.”
The company operates in more than 100 countries and is supported by over 45 manufacturing facilities approved by regulators such as the US Food and Drug Administration and the European Medicines Agency. Its portfolio spans therapeutic areas including cardiology, endocrinology, neurology, psychiatry, gastroenterology and oncology.
According to the company, the newly introduced portfolio is designed to address gaps in access to treatment, particularly for conditions such as hypertension, diabetes, liver disease and alimentary disorders. It includes bioequivalent and therapeutically equivalent medicines, some of which are positioned as first generics in their respective categories.
Generics, which are widely used in clinical practice, have been shown to deliver comparable efficacy and safety to innovator medicines when produced to established standards. The company said its products adhere to international quality and safety requirements.
Sharon Pablo, country head of Sun Pharma Philippines, said the initiative reflects a commitment to improving access to medicines.
“It is our commitment to Filipino patients to provide affordable, reliable, and high-quality branded generics — medicines built on global standards and proven scientific rigor,” Pablo said. “Through our mission of Reaching People, Touching Lives, we aim to expand access, empower care, and make meaningful health outcomes possible for every Filipino we serve.”
The launch also introduced the campaign “#SunKaNa,” presented through a program themed “The Golden Hour: The Best Hour,” which emphasized timely and coordinated care. The company said it is working toward securing regulatory approvals and expanding availability across the Philippines as part of its broader push to reach more patients.
